Updated:
Azitra, Inc.
Azitra, Inc. is a clinical-stage biotech engineering the skin microbiome to treat rare dermatologic diseases through live biotherapeutic candidates.
Azitra, Inc.
Azitra, Inc. develops engineered bacteria for topical application, targeting rare and serious skin conditions through precise genetic modification of commensal microbes. The company was founded with academic roots at Yale University and advances candidates derived from the human skin microbiome, not synthetic biology. Azitra deploys capital into clinical-trial execution for priority programs including a Phase 1b/2 trial for Netherton syndrome and preclinical work in atopic dermatitis and other inflammatory skin diseases. The company's platform, termed Intelligent Protein Synthesis, uses engineered Staphylococcus epidermidis to deliver therapeutic proteins directly at the site of disease. Confirmed public disclosures include a Phase 1b trial completion for lead candidate AZT-01 and an FDA clearance for a second Investigational New Drug application (per public record, 2023–2025). As a publicly traded entity (NYSE American: AZTR), Azitra is not structured as a family office or asset manager. The firm's operational footprint remains concentrated in North America, specifically Connecticut, where its research and lab facilities are based. Azitra has not disclosed a professional headcount or an executive team beyond founder-level leadership. Azitra's structural differentiator lies in its exclusive focus on living therapeutics for dermatology—a niche that separates it from larger biopharma firms pursuing monoclonal antibodies or small molecules. The company relies on a cost-efficient clinical development model and a targeted pipeline centered on orphan-designated rare skin diseases, which reduces trial scale and capital requirements compared to broad dermatology programs.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Azitra's core therapeutic approach?
Azitra engineers commensal skin bacteria—specifically Staphylococcus epidermidis—to produce and deliver therapeutic proteins directly to affected skin. This living therapeutic platform is designed for treating rare genetic skin diseases like Netherton syndrome and more prevalent conditions like atopic dermatitis (per public record).
Has Azitra advanced any candidates into clinical trials?
Yes. Azitra reported positive Phase 1b data for AZT-01 in Netherton syndrome and has received FDA clearance for a second Investigational New Drug application. The company also has preclinical programs in atopic dermatitis (per public record, 2023–2025).
Does Azitra operate as a family office or investment vehicle?
No. Azitra, Inc. is a publicly traded biotechnology company listed on the NYSE American under ticker AZTR. It is not structured as a family office, asset manager, or any allocator vehicle.
What is Azitra's geographic base of operations?
Azitra is headquartered in Branford, Connecticut, and conducts research and laboratory operations within the state. The company has not disclosed additional office locations outside North America.
Which specific diseases does Azitra's pipeline target?
Azitra's lead program targets Netherton syndrome, a rare autosomal recessive ichthyosis with an estimated prevalence of 1 in 200,000 births. The company also has early-stage programs for atopic dermatitis and other filaggrin-deficient skin conditions.
How does Azitra's platform differ from conventional topical drugs?
Azitra's platform uses live genetically modified bacteria that colonize the skin and continuously secrete therapeutic proteins locally. This contrasts with traditional topical creams or ointments which require repeated application and may have limited depth of penetration. The living system aims to provide sustained protein delivery at the disease site.
Does Azitra have disclosed financial backing or partnerships?
Azitra has not publicly disclosed a specific family-office or institutional backer. The company is publicly traded, which provides access to capital markets, and has historically raised equity through public offerings and warrants (per public records).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: